Ovarian cancer treatment depends on the exact histologic subtype, stage, extent of disease in the abdomen, previous treatment, general condition and molecular or hereditary findings that can affect the wider treatment plan. German university gynecologic-oncology centers publish pathways combining specialist imaging and pathology review, complex cytoreductive surgery, systemic treatment, genetics, recurrence assessment and clinical studies. International patients should therefore seek a multidisciplinary disease-level review rather than choosing one operation or technology in isolation.
Confirm the exact ovarian-cancer subtype and extent of disease
Heidelberg describes several ovarian-cancer histologies with different biological behavior and treatment implications. A useful review should therefore include pathology, pelvic assessment and cross-sectional imaging rather than relying on the label 'ovarian cancer' alone.
Staging usually combines gynecologic assessment, imaging and laboratory information
Heidelberg publishes a diagnostic pathway that includes gynecologic examination, vaginal ultrasound, laboratory markers such as CA-125 and CT or MRI for assessment of disease spread. The findings are then discussed in an interdisciplinary setting before treatment planning.
Cytoreductive surgery can be a central part of treatment
Heidelberg describes surgery as a central treatment component and emphasizes complete removal of visible tumor where feasible. These operations can require multivisceral surgery involving neighboring organs and close cooperation with visceral, hepatobiliary, thoracic, urologic or vascular surgeons. Charité likewise operates a dedicated ovarian-cancer competence center with specialized gynecologic-oncology surgery.
The timing of surgery and chemotherapy is individualized
Heidelberg documents chemotherapy both before surgery in selected cases and after surgery in others. The choice between primary surgery and a neoadjuvant-chemotherapy/intermediate-surgery pathway depends on disease distribution, resectability, general condition and the multidisciplinary assessment rather than a fixed sequence for every patient.
Genetic counseling can affect both the patient and the family
Heidelberg states that women with confirmed ovarian cancer should be offered human-genetic counseling because inherited BRCA mutations can influence prognosis and treatment and can also be relevant to relatives. International patients should send any existing germline or tumor-genetic results and ask whether additional testing is recommended before the treatment plan is finalized.
Maintenance treatment is a separate part of the pathway
Heidelberg describes maintenance therapy after chemotherapy in selected patients. The exact drug strategy changes with current evidence and individual tumor characteristics, so a portal page should not substitute a static medication list for current specialist review.
HIPEC is not a routine default for ovarian cancer
Heidelberg lists HIPEC among specialist gynecologic-oncology surgical capabilities and describes selected situations in which it can be considered. Charité explicitly notes that HIPEC is generally not indicated for ovarian cancer. Patients should therefore treat HIPEC as a specialist-review question rather than assuming that heated intraperitoneal chemotherapy is a standard component of ovarian-cancer surgery.
Recurrence requires a new multidisciplinary decision
Heidelberg describes recurrent ovarian cancer as a separate decision point in which repeat surgery, systemic treatment or a combination may be considered according to the interval since previous therapy, current disease distribution, general condition and patient priorities.
Records to send before travelling
A German gynecologic-oncology team should be able to reconstruct the diagnosis, prior treatment and current disease distribution before deciding whether surgery, systemic therapy or a second opinion is appropriate.
- Pathology report and, when requested, pathology slides or blocks
- Operative reports from previous abdominal or gynecologic surgery
- Current CT or MRI images in DICOM format and radiology reports
- CA-125 trend and relevant laboratory results
- Chemotherapy regimens, dates, doses and response information
- Previous maintenance or targeted treatment
- BRCA or other germline/tumor genetic test results when available
- Current symptoms, performance status and major comorbidities
- A clear question about primary surgery, interval surgery, recurrence surgery, systemic treatment or second opinion
Plan the full episode, not only the operation
For international patients, the practical treatment episode may include pathology review, staging, anesthesia assessment, major abdominal surgery, inpatient recovery, chemotherapy planning, genetic counseling and follow-up. Ask which parts must happen in Germany and which can safely be transferred to the oncology team at home.
Sources and review
This guide was last source-reviewed on 2026-08-30.